PDGFR-Β expression in small cell lung cancer patients

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 2, 2007, Pages 431-437

  Shinohara, Eric T ^a,b   Gonzalez, Adriana ^b   Massion, Pierre P ^b   Olson, Sandra J ^b   Albert, Jeffrey M ^b   Shyr, Yu ^b   Carbone, David P ^b   Johnson, David H ^b   Hallahan, Dennis E ^b   Lu, Bo ^b  

^a ABINGTON MEMORIAL HOSPITAL   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Biomarker; Lung cancer; Platelet derived endothelial growth factor; Prognosis; STI571; Tissue array

Indexed keywords

BIOMARKERS; DRUG PRODUCTS; GROWTH KINETICS; PATIENT TREATMENT; PULMONARY DISEASES;

ENDOTHELIAL GROWTH FACTORS; LUNG CANCER; PROGNOSIS; TISSUE ARRAYS;

TUMORS;

ANTIBODY; PARAFFIN; PLATELET DERIVED GROWTH FACTOR B;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW LEVEL LASER THERAPY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SMALL CELL; CHI-SQUARE DISTRIBUTION; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROGNOSIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 33846195395     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.08.060     Document Type: Article

References (50)

1. Laskin J., Sandler A., and Johnson D.H. An advance in small-cell lung cancer treatment-more or less. J Natl Cancer Inst 95 (2003) 1099-1101
2. von Pawel J., Schiller J.H., Shepherd F.A., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 (1999) 658-667
3. Turrisi III A.T., Kim K., Blum R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340 (1999) 265-271
4. De Ruysscher D., Pijls-Johannesma M., Bentzen S.M., et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24 (2006) 1057-1063
5. Baas P., Belderbos J.S., Senan S., et al. Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: A Dutch multicenter phase II study. Br J Cancer 94 (2006) 625-630
6. Kubota K., Nishiwaki Y., Sugiura T., et al. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Clin Cancer Res 11 (2005) 5534-5538
7. Ettinger D.S., Berkey B.A., Abrams R.A., et al. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: A Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol 23 (2005) 4991-4998
8. Murren J., Glatstein E., and Pass H.I. Small cell lung cancer. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: Principles and practice of oncology. Sixth edition (2001), Lippincott, Williams and Wilkins, Philadelphia
9. Pietras K., Sjoblom T., Rubin K., et al. PDGF receptors as cancer drug targets. Cancer Cell 3 (2003) 439-443
10. Bravo M., Vasquez R., Rubio H., et al. Production of platelet-derived growth factor by human lung cancer. Respir Med 85 (1991) 479-485
11. Heldin N.E., Usuki K., Bergh J., et al. Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines. Br J Cancer 68 (1993) 708-711
12. Forsberg K., Bergh J., and Westermark B. Expression of functional PDGF beta receptors in a human large-cell lung-carcinoma cell line. Int J Cancer 53 (1993) 556-560
13. Abrams T.J., Lee L.B., Murray L.J., et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2 (2003) 471-478
14. Decaudin D., de Cremoux P., Sastre X., et al. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. Int J Cancer 113 (2005) 849-856
15. Zhang P., Gao W.Y., Turner S., et al. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2 (2003) 1
16. Kawai T., Hiroi S., and Torikata C. Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest 77 (1997) 431-436
17. Yu J., Ustach C., and Kim H.R. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 36 (2003) 49-59
18. Lokker N.A., Sullivan C.M., Hollenbach S.J., et al. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62 (2002) 3729-3735
19. Geng L., Shinohara E.T., Kim D., et al. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int J Radiat Oncol Biol Phys 64 (2006) 263-271
20. Gilbertson R.J., and Clifford S.C. PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet 35 (2003) 197-198
21. Coltrera M.D., Wang J., Porter P.L., et al. Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res 55 (1995) 2703-2708
22. Wang W.L., Healy M.E., Sattler M., et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 19 (2000) 3521-3528
23. Golub T.R., Barker G.F., Lovett M., et al. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77 (1994) 307-316
24. Carroll M., Tomasson M.H., Barker G.F., et al. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci USA 93 (1996) 14845-14850
25. Sappino A.P., Carter S., Ellison M., et al. Plasma calcitonin in small cell lung cancer: Prognostic significance. Br J Cancer 48 (1983) 881-882
26. Sappino A.P., Ellison M.L., and Gusterson B.A. Immunohistochemical localisation of keratin in small cell carcinoma of the lung: Correlation with response to combination chemotherapy. Eur J Cancer Clin Oncol 19 (1983) 1365-1370
27. Souhami R.L., Bradbury I., Geddes D.M., et al. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 45 (1985) 2878-2882
28. Byhardt R.W., Hartz A., Libnoch J.A., et al. Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). Int J Radiat Oncol Biol Phys 12 (1986) 771-777
29. Blackhall F.H., Pintilie M., Michael M., et al. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res 9 (2003) 2241-2247
30. Oshita F., Kameda Y., Hamanaka N., et al. High expression of integrin beta1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer. Am J Clin Oncol 27 (2004) 215-219
31. Ando S., Suzuki M., Yamamoto N., et al. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Anticancer Res 24 (2004) 1941-1946
32. Wistuba I.I., Behrens C., Virmani A.K., et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 60 (2000) 1949-1960
33. Rohr U.P., Rehfeld N., Geddert H., et al. Prognostic relevance of fragile histidine triad protein expression in patients with small cell lung cancer. Clin Cancer Res 11 (2005) 180-185
34. Krystal G.W., Honsawek S., Litz J., et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6 (2000) 3319-3326
35. Kijima T., Maulik G., Ma P.C., et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 62 (2002) 6304-6311
36. Lonardo F., Pass H.I., and Lucas D.R. Immunohistochemistry frequently detects c-Kit expression in pulmonary small cell carcinoma and may help select clinical subsets for a novel form of chemotherapy. Appl Immunohistochem Mol Morphol 11 (2003) 51-55
37. Heinrich M.C. Is KIT an important therapeutic target in small cell lung cancer?. Clin Cancer Res 9 (2003) 5825-5828
38. Johnson B.E., Fischer T., Fischer B., et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 9 (2003) 5880-5887
39. Krug L.M., Crapanzano J.P., Azzoli C.G., et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: A phase II clinical trial. Cancer 103 (2005) 2128-2131
40. Dy G.K., Miller A.A., Mandrekar S.J., et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: A CALGB and NCCTG study. Ann Oncol 16 (2005) 1811-1816
41. Bergh J. The expression of the platelet-derived and transforming growth factor genes in human nonsmall lung cancer cell lines is related to tumor stroma formation in nude mice tumors. Am J Pathol 133 (1988) 434-439
42. Soderdahl G., Betsholtz C., Johansson A., et al. Differential expression of platelet-derived growth factor and transforming growth factor genes in small- and non-small-cell human lung carcinoma lines. Int J Cancer 41 (1988) 636-641
43. Lechner J.F., McClendon I.A., LaVeck M.A., et al. Differential control by platelet factors of squamous differentiation in normal and malignant human bronchial epithelial cells. Cancer Res 43 (1983) 5915-5921
44. Sihto H., Sarlomo-Rikala M., Tynninen O., et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 23 (2005) 49-57
45. Burger H., den Bakker M.A., Stoter G., et al. Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer 39 (2003) 793-799
46. Dy G.K., Miller A.A., Mandrekar S.J., et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: A CALGB and NCCTG study. Ann Oncol 16 (2005) 1811-1816
47. Johnson B.E. Imatinib for small cell lung cancer, aiming for a target in vivo. Clin Cancer Res 10 (2004) 3235-3236
48. Koukourakis M.I., Giatromanolaki A., O'Byrne K.J., et al. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer 75 (1997) 477-481
49. Fitzer-Attas C., Feldman M., and Eisenbach L. Expression of functionally intact PDGF-alpha receptors in highly metastatic 3LL Lewis lung carcinoma cells. Int J Cancer 53 (1993) 315-322
50. Shou Y., Hirano T., Gong Y., et al. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer 85 (2001) 1706-1712